Syntax Advisors’s Nektar Therapeutics NKTR Stock Holding History

Syntax Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,738	Closed	-$18.3K	–	230
2023 Q1	$18.3K	Buy	1,738 +955	+122%	+$28.9K	0.01%	232
2022 Q4	$26.6K	Buy	+783	New	+$37.9K	0.02%	212
2022 Q3	–	Sell	-712	Closed	-$41K	–	222
2022 Q2	$41K	Buy	+712	New	+$44.9K	0.03%	215

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Syntax Advisors's NKTR Position: Q2 2023 in Review

Syntax Advisors sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 1,738 shares — an estimated $18.3K sold.

Syntax Advisors first reported a position in NKTR in Q2 2022 and held it in 3 quarters. The position peaked at $41K in Q2 2022. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.

Syntax Advisors reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
Syntax Advisors sold 1,738 Nektar Therapeutics shares in Q2 2023, an estimated $18.3K.
Syntax Advisors first reported a position in Nektar Therapeutics in Q2 2022 and held it in 3 quarters.
Syntax Advisors's Nektar Therapeutics position peaked at $41K in Q2 2022.
146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.

Based on Syntax Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.